Caitlin Krebs is the co-founder and CEO of Nalu Bio, a company unlocking the endocannabinoid system—the body's own built-in balancing mechanism—through an AI-powered platform that designs novel cannabinoid-inspired small molecules to tackle pain, inflammation, endometriosis, and metabolic disease.
Before co-founding Nalu Bio, Caitlin spent over two decades at the intersection of science, technology, and commercialization, building and scaling companies across AI-driven drug discovery at Entelos, diabetes prevention at Tethys Bioscience, Alzheimer's prevention at Neurotrack, and early cancer detection at Bluestar Genomics—completing more than 50 strategic partnerships and product launches across biopharma, diagnostics, and digital health along the way.
At Nalu Bio, Caitlin leads an AI and in silico platform designing next-generation cannabinoid therapeutics targeting CB1 and CB2 receptors, and recently announced positive results for a cannabinoid-based treatment for endometriosis, a condition affecting 200 million women worldwide. With a $12 million Series A and a focus on one of medicine's most chronically underserved spaces, Caitlin's journey from a child tagging sea turtles in a Hawaiian lagoon to biotech founder demonstrates how two decades at the bleeding edge of science can converge into an entirely new class of medicines.
.png)
.png)